Holen Sie sich die Stockscreener-App
3.46
2.07%
0.08
Schlusskurs vom Vortag:
$3.38
Offen:
$3.37
24-Stunden-Volumen:
410.03K
Relative Volume:
0.69
Marktkapitalisierung:
$80.70M
Einnahmen:
$160.43M
Nettoeinkommen (Verlust:
$-227.64M
KGV:
-0.0503
EPS:
-68.77
Netto-Cashflow:
$-170.79M
1W Leistung:
+16.95%
1M Leistung:
+93.82%
6M Leistung:
+24.55%
1J Leistung:
-67.76%
1-Tages-Spanne:
$3.30
$3.56
1-Wochen-Bereich:
$2.83
$4.0597
52-Wochen-Spanne:
$1.38
$19.69
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Vergleichen Sie AGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.455 | 80.70M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.32 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.14 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
533.84 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.69 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
221.68 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AG - GuruFocus
Analyst Reiterates Neutral Rating for Agenus (AGEN) | AGEN Stock News - GuruFocus
Agenus (AGEN) Target Price Raised by Analyst Baird | AGEN Stock News - GuruFocus
Agenus (AGEN) Receives Price Target Increase from Baird | AGEN S - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Agenus names Dr Richard Goldberg as CDO - Medical Buyer
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Mo - GuruFocus
Agenus Inc. Reports Q1 2025 Progress and Financials - TipRanks
Agenus Inc. Earnings Call: Optimism Amid Challenges - TipRanks
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances - MSN
Agenus (AGEN) Moves to Sell 165,000 Shares of Common Stock - GuruFocus
Agenus: Q1 Earnings Snapshot - MySA
Agenus appoints oncology veteran Dr. Goldberg as CDO By Investing.com - Investing.com Canada
Agenus (AGEN) Sets Strategic Path with New Leadership and Transactions - GuruFocus
Transcript : Agenus Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Agenus reports Q1 EPS ($1.03), consensus ($1.98) - TipRanks
Earnings call transcript: Agenus reports Q1 2025 net loss, stock rises premarket - Investing.com
Agenus (AGEN) Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer | AGEN Stock News - GuruFocus
Agenus (AGEN) Reports Q1 Earnings, Beats EPS Estimates - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings: EPS Beats Estimates at -$1.0 - GuruFocus
Agenus Reports Q1 2025 Financial Results and Key Business Updates | AGEN Stock News - GuruFocus
AGEN Welcomes Renowned Cancer Expert Dr. Richard Goldberg as Chi - GuruFocus
Dr. Richard Goldberg Joins Agenus as Chief Development Officer - citybiz
Renowned Gi Oncology Leader Dr. Richard Goldberg Joins Agenus As Chief Development Officer - marketscreener.com
Agenus Reports Q1 2025 Financial Results and Key Business Updates - Stock Titan
Agenus appoints oncology veteran Dr. Goldberg as CDO - Investing.com
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Eagle-Tribune
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Re - GuruFocus
Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Revisions - GuruFocus
Lost Money on Agenus Inc. (AGEN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class ActionAGEN - ACCESS Newswire
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report | AGEN Stock News - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for Investors - Stock Titan
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):